Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Pentoxifylline: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 11:44, 5 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 462584485 of page Pentoxifylline for the Chem/Drugbox validation project (updated: 'DrugBank').  Latest revision as of 06:09, 19 May 2024 edit GreenLipstickLesbian (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers, Pending changes reviewers13,364 edits →Medical uses: fixed cc by 4 attribution for content addedhttps://en.wikipedia.org/search/?diff=1084465408&oldid=1084147727 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790020/Tag: 2017 wikitext editor 
Line 1: Line 1:
{{Short description|Chemical compound}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Drugbox {{Drugbox
| Watchedfields = changed | Watchedfields = changed
| verifiedrevid = 408793562 | verifiedrevid = 464198476
| IUPAC_name = 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1''H''-purine-2,6-dione | IUPAC_name = 3,7-Dimethyl-1-(5-oxohexyl)purine-2,6-dione
| image = Pentoxifylline.png | image = Pentoxifylline.svg
| width = 180
| image2 = Pentoxifylline xtal 2005 ball-and-stick.png
| width2 = 200


<!--Clinical data--> <!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|p|ɛ|n|t|ɒ|k|ˈ|s|ɪ|f|ᵻ|l|iː|n|,_|-|ɪ|n}}
| tradename = Trental
| tradename = Trental, many other names worldwide<ref name=generics/>
| Drugs.com = {{drugs.com|monograph|pentoxifylline}} | Drugs.com = {{drugs.com|monograph|pentoxifylline}}
| MedlinePlus = a685027 | MedlinePlus = a685027
| licence_US = Pentoxifylline
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = B1
| pregnancy_US = C | pregnancy_US = C
| pregnancy_category = | pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_AU = S4
| legal_CA = Rx-only
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | legal_UK = POM
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = Rx-only
| legal_status = | legal_status =
| routes_of_administration = Oral | routes_of_administration = ]


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = 10–30%<ref name = MSR>{{cite web|title=Trental, Pentoxil (pentoxifylline) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|access-date=3 February 2014|url=http://reference.medscape.com/drug/trental-pentoxil-pentoxifylline-342179#showall}}</ref>
| bioavailability = Near 100% for oral dosing
| protein_bound = | protein_bound =
| metabolism = Hepatic and via erythrocytes | metabolism = ] and via ]
| elimination_half-life = 0.4 - 0.8 hours (1 - 1.6 hours for active metabolite) | elimination_half-life = 0.4–0.8 hours (1–1.6 hours for active metabolite)<ref name = MSR/>
| excretion = Mainly urine (<4% feces) | excretion = Urine (95%), faeces (<4%)<ref name = MSR/>


<!--Identifiers--> <!--Identifiers-->
| IUPHAR_ligand = 7095
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 6493-05-6 | CAS_number = 6493-05-6
Line 44: Line 49:
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 628 | ChEMBL = 628
|synonyms=oxpentifylline (former ])<ref name = TGA>{{cite web|title=PRODUCT INFORMATION TRENTAL® 400|work=TGA eBusiness Services|publisher=sanofi-aventis australia pty limited|date=25 March 2010|access-date=3 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06086-3|format=PDF}}</ref>

<!--Chemical data--> <!--Chemical data-->
| C=13 | H=18 | N=4 | O=3 | C=13 | H=18 | N=4 | O=3
| molecular_weight = 278.31
| smiles = O=C2N(c1ncn(c1C(=O)N2CCCCC(=O)C)C)C | smiles = O=C2N(c1ncn(c1C(=O)N2CCCCC(=O)C)C)C
| InChI = 1/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
| InChIKey = BYPFEZZEUUWMEJ-UHFFFAOYAP
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 | StdInChI = 1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
Line 56: Line 58:
| StdInChIKey = BYPFEZZEUUWMEJ-UHFFFAOYSA-N | StdInChIKey = BYPFEZZEUUWMEJ-UHFFFAOYSA-N
}} }}

'''Pentoxifylline''', also known as '''oxpentifylline''', is a ] derivative used as a drug to treat muscle pain in people with ].<ref name=":0">{{cite journal | vauthors = Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K | title = Pentoxifylline for intermittent claudication | journal = The Cochrane Database of Systematic Reviews | volume = 2020 | issue = 10 | pages = CD005262 | date = October 2020 | pmid = 33063850 | pmc = 8094235 | doi = 10.1002/14651858.CD005262.pub4 }}</ref> It is ] and sold under many brand names worldwide.<ref name=generics>Drugs.com . Page accessed Feb 1, 206</ref>

== Medical uses ==
Its primary use in medicine is to reduce pain, cramping, numbness, or weakness in the arms or legs which occurs due to ], a form of muscle pain resulting from ]s.<ref name=":0" /> This is its only ], ] and ]-labelled indication.<ref name = TGA/><ref name = DM>{{cite web|title=PENTOXIFYLLINE tablet, extended release |work=DailyMed|publisher=Apotex Corp.|date=February 2013|access-date=3 February 2014|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40ae2d9a-0d95-640d-0640-f76e7e1a13cb#nlm34067-9}}</ref><ref name = EMC>{{cite web|title=Trental 400 - Summary of Product Characteristics (SPC)|work=electronic Medicines Compendium|publisher=Sanofi|date=10 October 2013|access-date=3 February 2014|url=http://www.medicines.org.uk/emc/medicine/338/SPC/Trental+400/}}</ref> However, pentoxifylline is also recommended for ] use as an adjunct to ] for the treatment of ] by the ] (SIGN) <ref>SIGN (2010) Management of chronic venous leg ulcers. Clinical guideline No. 120. Scottish Intercollegiate Guidelines Network. www.sign.ac.uk {{ISBN|978-1-905813-66-7}}</ref> as this has been shown to improve healing rates.<ref name="JullArroll2012">{{cite journal | vauthors = Jull AB, Arroll B, Parag V, Waters J | title = Pentoxifylline for treating venous leg ulcers | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD001733 | date = December 2012 | issue = 12 | pmid = 23235582 | pmc = 7061323 | doi = 10.1002/14651858.CD001733.pub3 }}</ref>

Pentoxifylline has been tested for use in ] patients as an alternative or compliment to ] and other steroids, as the drug can inhibit excess levels of ], which is associated with ] formation.<ref>{{cite journal | vauthors = Zabel P, Entzian P, Dalhoff K, Schlaak M | title = Pentoxifylline in treatment of sarcoidosis | journal = American Journal of Respiratory and Critical Care Medicine | volume = 155 | issue = 5 | pages = 1665–1669 | date = May 1997 | pmid = 9154873 | doi = 10.1164/ajrccm.155.5.9154873 }}</ref><ref>{{cite journal | vauthors = Park MK, Babaali H, Gilbert-McClain LI, Stylianou M, Joo J, Moss J, Manganiello VC | title = Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis | journal = Sarcoidosis, Vasculitis, and Diffuse Lung Diseases | volume = 26 | issue = 2 | pages = 121–131 | date = July 2009 | pmid = 20560292 | pmc = 2946799 }}</ref><ref>{{cite journal | vauthors = Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U | title = Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone | journal = Chest | volume = 124 | issue = 4 | pages = 1526–1532 | date = October 2003 | pmid = 14555589 | doi = 10.1378/chest.124.4.1526 }}</ref>
It has further been used to treat immunologic reactions to ] with some success.<ref>{{cite journal | vauthors = Legendre DP, Muzny CA, Swiatlo E | title = Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions | journal = Pharmacotherapy | volume = 32 | issue = 1 | pages = 27–37 | date = January 2012 | pmid = 22392826 | doi = 10.1002/PHAR.1009 | s2cid = 46569413 }}</ref>
Benefit in ] was shown, with some studies demonstrating a reduction in risk of ].{{citation needed|date=September 2019}}
For ], Pentoxifylline has been used to improve ] quality and motility<ref>{{cite journal | vauthors = Mahaldashtian M, Khalili MA, Nottola SA, Woodward B, Macchiarelli G, Miglietta S | title = Does in vitro application of pentoxifylline have beneficial effects in assisted male reproduction? | journal = Andrologia | volume = 53 | issue = 1 | pages = e13722 | date = February 2021 | pmid = 33112447 | doi = 10.1111/and.13722 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Baldini D, Ferri D, Baldini GM, Lot D, Catino A, Vizziello D, Vizziello G | title = Sperm Selection for ICSI: Do We Have a Winner? | journal = Cells | volume = 10 | issue = 12 | date = December 2021 | page = 3566 | pmid = 34944074 | doi = 10.3390/cells10123566 | pmc = 8700516 | doi-access = free }}</ref> and as safe oral drug in the treatment of male ] with ].<ref>{{cite journal | vauthors = Lu Y, Su H, Zhang J, Wang Y, Li H | title = Treatment of Poor Sperm Quality and Erectile Dysfunction With Oral Pentoxifylline: A Systematic Review | journal = Frontiers in Pharmacology | date = 2022 | volume = 12 | pages = 789787 | pmid = 35095501 | doi = 10.3389/fphar.2021.789787 | pmc = 8790020 | doi-access = free }}{{Creative Commons text attribution notice|cc=by4|from this source=yes}}</ref><ref>{{cite journal | vauthors = Korenman SG, Viosca SP | title = Treatment of vasculogenic sexual dysfunction with pentoxifylline | journal = Journal of the American Geriatrics Society | volume = 41 | issue = 4 | pages = 363–366 | date = April 1993 | pmid = 8463520 | doi = 10.1111/j.1532-5415.1993.tb06941.x | s2cid = 35396795 }}</ref>

An interesting off-label indication of pentoxifylline is the supportive treatment of distal ], where it can be added, for example, to ] or ].<ref>{{cite journal | vauthors = Hosseini F, Mohammadbeigi A, Aghaali M, Borujerdi R, Parham M | title = Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial | journal = Journal of Research in Medical Sciences | volume = 24 | issue = 1 | pages = 89 | date = 2019 | pmid = 31741661 | pmc = 6856542 | doi = 10.4103/jrms.JRMS_115_18 | doi-access = free }}</ref> Theoretically, it can (among other things) act prophylactically against ulcerative changes of the lower limbs associated with chronically decompensated diabetes. Patients with measurable impairment in arterial supply are more likely to benefit from adjunctive treatment with pentoxifylline.<ref>{{cite journal | vauthors = Page JC, Chen EY | title = Management of painful diabetic neuropathy. A treatment algorithm | journal = Journal of the American Podiatric Medical Association | volume = 87 | issue = 8 | pages = 370–379 | date = August 1997 | pmid = 9274092 | doi = 10.7547/87507315-87-8-370 }}</ref> The administration of higher doses of pentoxifylline in hospitalization for complications of distal diabetic neuropathy is usually conditioned by the joint agreement of the neurologist with the physicians of internal medicine (diabetology and angiology).

The combination of ] and pentoxifylline has been evaluated for the treatment of medication-related ] of the jaw.<ref>{{cite journal | vauthors = de Carvalho EF, Bertotti M, Migliorati CA, Rocha AC | title = Cilostazol and Tocopherol in the Management of Medication-Related Osteonecrosis of the Jaw: New Insights From a Case Report | journal = Journal of Oral and Maxillofacial Surgery | volume = 79 | issue = 12 | pages = 2499–2506 | date = December 2021 | doi = 10.1016/j.joms.2021.06.036 | pmid = 34339622 | s2cid = 236884968 | url = https://www.practiceupdate.com/content/adjunctive-effect-of-pentoxifylline-and-tocopherol-in-the-management-of-medication-related-osteonecrosis-of-the-jaw/155064 | access-date = 2023-09-04 }}</ref>

Pentoxifylline may be used transdermally for cellulite treatment.

==Adverse effects==
Common side effects are belching, bloating, stomach discomfort or upset, nausea, vomiting, ], dizziness, and flushing. Uncommon and rare side effects include angina, palpitations, hypersensitivity, ], rash, ], bleeding, hallucinations, arrhythmias, and ].<ref name = TGA/><ref name = MSR/><ref name = DM/><ref name = EMC/>

Contraindications include intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral haemorrhage, and risk factors for haemorrhage.<ref name = MSR/>

== Mechanism ==
Like other methylated ], pentoxifylline is a competitive nonselective ]<ref name="PDEs-Essayan">{{cite journal | vauthors = Essayan DM | title = Cyclic nucleotide phosphodiesterases | journal = The Journal of Allergy and Clinical Immunology | volume = 108 | issue = 5 | pages = 671–680 | date = November 2001 | pmid = 11692087 | doi = 10.1067/mai.2001.119555 | doi-access = free }}</ref> which raises intracellular ], activates ], ]<ref name="PTX-Deree">{{cite journal | vauthors = Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R | title = Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition | journal = Clinics | volume = 63 | issue = 3 | pages = 321–328 | date = June 2008 | pmid = 18568240 | pmc = 2664230 | doi = 10.1590/S1807-59322008000300006 }}</ref><ref name="pmid9927365">{{cite journal | vauthors = Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U | title = Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages | journal = American Journal of Respiratory and Critical Care Medicine | volume = 159 | issue = 2 | pages = 508–511 | date = February 1999 | pmid = 9927365 | doi = 10.1164/ajrccm.159.2.9804085 }}</ref> and ]<ref name="LT-Peters-Golden">{{cite journal | vauthors = Peters-Golden M, Canetti C, Mancuso P, Coffey MJ | title = Leukotrienes: underappreciated mediators of innate immune responses | journal = Journal of Immunology | volume = 174 | issue = 2 | pages = 589–594 | date = January 2005 | pmid = 15634873 | doi = 10.4049/jimmunol.174.2.589 | doi-access = free }}</ref> synthesis, and ] and ].<ref name="LT-Peters-Golden"/> In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and blood clot formation.<ref>{{cite journal | vauthors = Ward A, Clissold SP | title = Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy | journal = Drugs | volume = 34 | issue = 1 | pages = 50–97 | date = July 1987 | pmid = 3308412 | doi = 10.2165/00003495-198734010-00003 | s2cid = 195697501 }}</ref> Pentoxifylline is also an antagonist at ] 2 receptors.<ref name="pmid18220696">{{cite journal | vauthors = Rodríguez-Morán M, Guerrero-Romero F | title = Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes | journal = Current Diabetes Reviews | volume = 4 | issue = 1 | pages = 55–62 | date = February 2008 | pmid = 18220696 | doi = 10.2174/157339908783502343 }}</ref>

==Research==
There is some evidence that pentoxifylline can lower the levels of some ] in non-alcoholic ] but evidence is insufficient to determine if the drug is safe and effective for this use.<ref>{{cite journal | vauthors = Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S | title = Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease | journal = Lipids in Health and Disease | volume = 10 | pages = 49 | date = April 2011 | pmid = 21477300 | pmc = 3088890 | doi = 10.1186/1476-511X-10-49 | doi-access = free }}</ref> Animal studies have been conducted exploring the use of pentoxifylline for ]<ref>{{cite journal | vauthors = Anele UA, Morrison BF, Burnett AL | title = Molecular pathophysiology of priapism: emerging targets | journal = Current Drug Targets | volume = 16 | issue = 5 | pages = 474–483 | year = 2015 | pmid = 25392014 | pmc = 4430197 | doi = 10.2174/1389450115666141111111842 }}</ref> and ].<ref>{{cite journal | vauthors = Latoni J, Shivapuja B, Seidman MD, Quirk WS | title = Pentoxifylline maintains cochlear microcirculation and attenuates temporary threshold shifts following acoustic overstimulation | journal = Acta Oto-Laryngologica | volume = 116 | issue = 3 | pages = 388–394 | date = May 1996 | pmid = 8790737 | doi = 10.3109/00016489609137862 }}</ref> Human studies have been conducted for ].<ref>{{cite journal | vauthors = El-Sakka AI | title = Reversion of penile fibrosis: Current information and a new horizon | journal = Arab Journal of Urology | volume = 9 | issue = 1 | pages = 49–55 | date = March 2011 | pmid = 26579268 | pmc = 4149188 | doi = 10.1016/j.aju.2011.03.013 }}</ref>

Pentoxifylline, in combination with ] and ], has been found to heal refractory ] of the jaw,<ref name="pmid20638190">{{cite journal | vauthors = Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL | title = Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial | journal = International Journal of Radiation Oncology, Biology, Physics | volume = 80 | issue = 3 | pages = 832–9 | date = July 2011 | pmid = 20638190 | doi = 10.1016/j.ijrobp.2010.03.029 | doi-access = free }}</ref>
and to be prophylactic against osteoradionecrosis.<ref name="pmid26975577">{{cite journal | vauthors = Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M | title = Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck | journal = The British Journal of Oral & Maxillofacial Surgery | volume = 54 | issue = 5 | pages = 547–50 | date = June 2016 | pmid = 26975577 | doi = 10.1016/j.bjoms.2016.02.024 }}</ref>

In a Cochrane systematic review on the use of pentoxifylline for intermittent claudication in 2015, the following was concluded "The quality of included studies was generally low, and very large variability between studies was noted in reported findings including duration of trials, doses of pentoxifylline and distances participants could walk at the start of trials. Most included studies did not report on <abbr>randomisation</abbr> techniques or how treatment allocation was concealed, did not provide adequate information to permit judgement of selective reporting and did not report <abbr>blinding</abbr> of <abbr>outcome</abbr> assessors. Given all these factors, the role of pentoxifylline in intermittent <abbr>claudication</abbr> remains uncertain, although this medication was generally well tolerated by participants".<ref>{{cite journal | vauthors = Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA | title = Pentoxifylline for intermittent claudication | journal = The Cochrane Database of Systematic Reviews | volume = 9 | issue = 9 | pages = CD005262 | date = September 2015 | pmid = 26417854 | pmc = 6513423 | doi = 10.1002/14651858.cd005262.pub3 }}</ref>{{Update inline|reason=Updated version https://www.ncbi.nlm.nih.gov/pubmed/33063850|date = December 2020}}

== See also ==
* ], an active metabolite of pentoxifylline
*]
* ], a PDE-3 inhibitor with better evidence for intermittent claudication on the Cochrane review cited above.

== References ==
{{reflist|2}}

== External links ==
*

{{Peripheral vasodilators}}
{{Phosphodiesterase inhibitors}}
{{Purinergics}}

]
]
]
]
]
]
]